Sihi Mutthu Bhagya: Siddaramaiah gets a surprise kiss from female fan in public

Udupi, Jun 16: A young software engineer died on board a bus bound for Udupi’s Kundapura from Bengaluru due to suspected cardiac arrest this morning.

The deceased has been identified as Chaitanya (25), son of Vishnu Murthy, a resident of Kumbri in Koteshwar in Kundapura taluk. He was working for a software firm Bengaluru.

Chaitanya had boarded a ‘Durgamba’ bus from Bengaluru at 9 pm on June 15. At around 6.30 am on June 16, he called his father and informed that the bus had reached Barkur.

When his father called Chaitanya again at around 7.30 am, the bus driver answered the call and told him that his son had fallen ill and been taken to Vinaya hospital in Kundapur.

Vishnu Murthy rushed to the hospital, but was informed by the doctors that Chaitanya was declared brought dead.

A case has been registered at Kundapura police station. Even though it is suspected that he died of cardiac arrest, the exact cause will be known only after the post-mortem.

Mangaluru, May 4: In line with the directive of the Deputy Commissioner against opening textile shops even after the relaxation of lockdown, it has been decided to continue the closure of all textile shops in Hampankatta area of Mangaluru until the end of the blessed Ramadan, President of KTA Youth Forum said on Monday.

Pointing out that several rumours were doing the rounds in social media on the opening of textile shops in the wake of Eid, the owners of textile shops met on Monday morning and unanimously decided against opening the shops. The association said the local MLA has also been consulted on the issue.

KTA Youth Forum is an organisation of owners of shops at Kunil Centre in Tokyo Market and Akbar Complex here, mostly comprising of Muslims.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.